- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Grace Therapeutics, Inc.(GRCE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GRCE
11/13/2026: GRCE (1-star) is currently NOT-A-BUY. Pass it for now.
Grace Therapeutics is a micro-cap, clinical-stage biopharmaceutical company specializing in proprietary drug formulations for rare and orphan diseases. The company's primary strength lies in its late-stage pipeline candidate, GTx-104, designed to treat aneurysmal subarachnoid hemorrhage. Its main growth opportunity centers on clearing regulatory hurdles and achieving commercialization. However, the company faces substantial execution risks, continuous cash burn, and dependence on external financing. The stock suits high-risk growth investors willing to tolerate volatility while monitoring regulatory updates and cash runway milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth optionality tied to clinical milestones, tempered by early-stage pipeline risks. |
| Momentum investor | Strong fit while signal remains positive | Short-term momentum can spike around major clinical data readouts and regulatory updates, conditional on positive price trends. |
| Value investor | Weak fit | The absence of commercial earnings and ongoing cash burn make traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company is pre-revenue and does not pay dividends, retaining all cash for clinical development. |
| Low-risk investor | Weak fit | High share price volatility and binary clinical-regulatory outcomes present substantial risk for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap clinical-stage biotech stocks frequently experience sharp price swings based on news flow and market sentiment. |
| Valuation risk | High | Valuation relies heavily on speculative future cash flows from unapproved drug candidates. |
| Competition risk (specialty pharma and orphan drug developers) | Medium / high | The company faces intense competition from well-funded peers targeting similar rare disease indications. |
| Business quality | Medium | The underlying asset quality is defined by promising drug delivery technology, though commercial proof remains pending. |
| Dividend income | Low / none | No dividend is paid or anticipated in the near term. |
| Execution risk | High | Success depends entirely on successfully managing clinical trials, manufacturing standards, and regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.08M USD | Price to earnings Ratio - | 1Y Target Price 5.85 |
Price to earnings Ratio - | 1Y Target Price 5.85 | ||
Volume (30-day avg) 104.1K shares | Beta 0.41 | 52 Weeks Range 1.67 - 5.18 | Updated Date 11/15/2026 |
52 Weeks Range 1.67 - 5.18 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -39.25% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Operations / Product Sales | Currently pre-revenue, future monetization is expected to stem from commercializing specialized pharmaceutical products for rare diseases. | The company does not currently sell commercial drugs for profit; investors are betting on future regulatory approvals. |
| Licensing and Partnerships | Potential future milestone payments, upfront fees, and royalties derived from co-development or commercialization agreements. | Strategic partnerships could provide non-dilutive funding and validation for pipeline assets. |
Valuation
Trailing PE - | Forward PE 2.17 | Enterprise Value 16.76M | Price to Sales(TTM) 197.75 |
Enterprise Value 16.76M | Price to Sales(TTM) 197.75 | ||
Enterprise Value to Revenue 5.5 | Enterprise Value to EBITDA 19.61 | Shares Outstanding 21.04M | Shares Floating 13.27M |
Shares Outstanding 21.04M | Shares Floating 13.27M | ||
Percent Insiders 18.68 | Percent Institutions 33.05 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

